Anthera Pharmaceuticals, Inc. (ANTH)

OTCMKTS · Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST
Market Cap 26.00
Revenue (ttm) n/a
Net Income (ttm) -24.93M
Shares Out 26.18M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 5,555
Open 0.0002
Previous Close 0.0002
Day's Range 0.0002 - 0.0002
52-Week Range 0.0001 - 0.0002
Beta -63.15
RSI 45.93
Earnings Date n/a

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 21
Stock Exchange OTCMKTS
Ticker Symbol ANTH
Full Company Profile

Financial Performance

Financial Statements

News

AM Best Assigns Issue Credit Ratings to Anthem, Inc.'s New Senior Unsecured Notes

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has assigned Long Term Issue Credit Ratings of “bbb+” to the newly issued senior unsecured notes of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE:ANTH], which ...

4 years ago - Business Wire

AM Best Comments on Credit Ratings of Anthem, Inc. and Its Subsidiaries Following MMM Holdings, LLC Acquisition Announcement

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has commented that the Credit Ratings (ratings) of Anthem, Inc. (Anthem) (Indianapolis, IN) [NYSE: ANTH] and its insurance subsidiaries remain unchanged followi...

4 years ago - Business Wire